1-(4-Methylamino-phenyl)-propan-2-one | 36798-48-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-(4-Methylamino-phenyl)-propan-2-one
• 英文别名: 1-[4-(Methylamino)phenyl]propan-2-one
• CAS: 36798-48-8
• 化学式: C₁₀H₁₃NO
• 分子量: 163.219
• InChiKey: DGXNKDUJXDBRBT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• NOVEL MULTIMERIC MOLECULES, A PROCESS FOR PREPARING THE SAME AND THE USE THEREOF FOR MANUFACTURING MEDICINAL DRUGS
  申请人：Guichard Gilles

  公开号：US20100136034A1

  公开（公告）日：2010-06-03

  The invention relates to a compound of the formula (I): in which k and j are independently 0 or 1, Y is a macrocycle in which the cycle includes 9 to 36 carbon atoms and is functionalised by three amino functions and by a chain for attaching the spacer arm Z via an X bond, R c is a binding pattern with a receptor of the TNF superfamily, X is a chemical function for binding the Y group to the space arm, and Z is a bi-, tri- or tetra-functional spacer arm.

  该发明涉及以下式（I）的化合物： 其中k和j独立地为0或1，Y是一个大环，其中该环包括9至36个碳原子，并且通过三个氨基功能和通过链将间隔臂Z通过X键连接的功能化，Rc是与TNF超家族受体的结合模式，X是用于将Y基固定到空间臂的化学功能，Z是双功能、三功能或四功能间隔臂。
• NOVEL MULTIMERIC CD40 LIGANDS, METHOD FOR PREPARING SAME AND USE THEREOF FOR PREPARING DRUGS
  申请人：Guichard Gilles

  公开号：US20100183642A1

  公开（公告）日：2010-07-22

  The invention concerns a compound of formula (I), wherein Y represents a macrocycle whereof the cycle comprises 9 to 36 atoms, and is functionalized by three amine or COOH functions; R c represents a group of formula H—X a —X b —X c —X d —X e —(X f ) i —, wherein i represents 0 or 1, X n is in particular selected among lysine, arginine, ornithine residues, X b is in particular selected among glycine, asparagine, L-proline or D-proline residues, X c et X d are in particular selected among tyrosine, phenylalanine or 3-nitrotyrosine residues, X e et X f are in particular selected among the following amino acid residues: NH 2 —(CH 2 ) n —COOH, n ranging from 1 to 10 or NH 2 —(CH 2 —CH 2 —O) m —CH 2 CH 2 COOH, m ranging from 3 to 6, provided that one at least of the amino acid residues X a , X b , X c and X d is different from the corresponding amino acid in the sequence of the natural CD40 143 Lys-Gly-Tyr-Tyr 146 fragment

  该发明涉及一种化合物，其化学式为（I），其中Y代表一个大环，该环包含9至36个原子，并且通过三个胺基或COOH功能官能化；Rc代表一个化学式为H—Xa—Xb—Xc—Xd—Xe—（Xf）i—的基团，其中i代表0或1，Xn特别选自赖氨酸、精氨酸、鸟氨酸残基之一，Xb特别选自甘氨酸、天冬氨酸、L-脯氨酸或D-脯氨酸残基之一，Xc和Xd特别选自酪氨酸、苯丙氨酸或3-硝基酪氨酸残基之一，Xe和Xf特别选自以下氨基酸残基之一：NH2—（CH2）n—COOH，其中n取1至10之间的值，或NH2—（ — —O）m— COOH，其中m取3至6之间的值，前提是氨基酸残基Xa、Xb、Xc和Xd中至少有一个与天然CD40143Lys-Gly-Tyr-Tyr146片段中相应的氨基酸不同。
• Amide Compound
  申请人：Matsumoto Takahiro

  公开号：US20080312226A1

  公开（公告）日：2008-12-18

  There is provided a FAAH inhibitor and a prophylactic or therapeutic agent for cerebrovascular disorders or sleep disorders comprising it. The prophylactic or therapeutic agent comprises a compound of the formula (I 0 ): R 1 —C—R 2 —R 3 —R 4 (I 0 ) wherein Z is oxygen or sulfur; R 1 is aryl which may be substituted, or a heterocyclic group which may be substituted; R 1a is a hydrogen atom, a hydrocarbon group which may be substituted, hydroxyl, etc.; R 2 is piperidin-1,4-diyl which may be substituted, or piperazin-1,4-diyl which may be substituted; R 3 is a group formed by eliminating two hydrogen atoms from a 5-membered aromatic heterocyclic group having 1 to 3 heteroatoms selected from nitrogen, oxygen and sulfur, which may be further substituted, —CO—, etc.; and R 4 is a hydrocarbon group which may be substituted, or a heterocyclic group which may be substituted; or a salt thereof.

  提供了一种FAAH抑制剂和预防或治疗脑血管疾病或睡眠障碍的药物，其中预防或治疗剂包括化合物(I0)的一种：R1-C-R2-R3-R4(I0)，其中Z为氧或硫；R1为芳基，可以被取代，或者是可以被取代的杂环基；R1a为氢原子，可以被取代的碳氢基，羟基等；R2为可以被取代的哌啶-1,4-二基，或者可以被取代的哌嗪-1,4-二基；R3为从具有1到3个氮、氧和硫杂原子的5元芳香杂环基中消除两个氢原子形成的基团，可以进一步被取代，-CO-等；R4为可以被取代的碳氢基或者可以被取代的杂环基；或其盐。
• AMIDE COMPOUND
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP1813606A1

  公开（公告）日：2007-08-01

  There is provided a FAAH inhibitor and a prophylactic or therapeutic agent for cerebrovascular disorders or sleep disorders comprising it. The prophylactic or therapeutic agent comprises a compound of the formula (I0): wherein Z is oxygen or sulfur; R1 is aryl which may be substituted, or a heterocyclic group which may be substituted; R1a is a hydrogen atom, a hydrocarbon group which may be substituted, hydroxyl, etc.; R2 is piperidin-1,4-diyl which may be substituted, or piperazin-1,4-diyl which may be substituted; R3 is a group formed by eliminating two hydrogen atoms from a 5-membered aromatic heterocyclic group having 1 to 3 heteroatoms selected from nitrogen, oxygen and sulfur, which may be further substituted, -CO-, etc.; and R4 is a hydrocarbon group which may be substituted, or a heterocyclic group which may be substituted; or a salt thereof.

  本发明提供了一种 FAAH 抑制剂和一种用于脑血管疾病或睡眠障碍的预防或治疗剂。该预防或治疗剂包括式（I0）化合物： 其中 Z 是氧或硫；R1 是可被取代的芳基或可被取代的杂环基团；R1a 是氢原子、可被取代的烃基、羟基等。R2 是可被取代的哌啶-1,4-二基或可被取代的哌嗪-1,4-二基；R3 是通过从具有 1 至 3 个选自氮、氧和硫的杂原子的 5 元芳香杂环基团中消除两个氢原子而形成的基团，该基团可被进一步取代、-CO- 等；以及 R4 是可被取代的烃基或可被取代的杂环基；或其盐。
• NPR-B agonists
  申请人：Shire Orphan Therapies GmbH

  公开号：US10196423B2

  公开（公告）日：2019-02-05

  Disclosed are novel compounds having NPR-B agonistic activity. Preferred compounds are linear peptides containing 8-13 conventional or non-conventional L- or D-amino acid residues connected to one another via peptide bonds.

  所公开的是具有 NPR-B 激动活性的新型化合物。优选化合物是线性肽，含有 8-13 个通过肽键相互连接的常规或非常规 L 或 D 氨基酸残基。